Fentanyl-Bupivacaine HCL Pf Injectable 3000mcg-12mg/Ml
Non-Sterility
18,003 recalls, newest first
Non-Sterility
Non-Sterility
Non-Sterility
An extraneous peak was observed for dissolution testing.
An extraneous peak was observed for dissolution testing.
An extraneous peak was observed for dissolution testing.
CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
Discoloration.
Out-of-specification organic impurity results obtained during routine stability testing.
Labeling: Not Elsewhere Classified. Container packaging is made, formed or filled to be misleading, resembling food and drink pouches
Failed Impurities/Degradation - Out-of-specification results for Fluocinolone Acetonide impurity.
Microbial Contamination of a Non-Sterile Product: Product tested positive for Cronobacter Sakazakii.
Microbial Contamination of a Non-Sterile Product: Product tested positive for Cronobacter Sakazakii.
Microbial Contamination of a Non-Sterile Product: Product tested positive for Cronobacter Sakazakii.
Failed Impurties/Degradation Specifications: out of specification results for an impurity for one lot
Presence of Foreign Tablets/Capsules: Metformin 1000mg with different imprint was found in bottles.
CGMP Deviations: product manufactured at the same facility that produced product that FDA sampled and found to be subpotent for ethanol and contained methanol.
Subpotent Drug: Product testing identified a decreased level of the active ingredient, Cysteamine HCl.
CGMP Deviations: Detection of N-nitrosodimethylamine (NDMA) impurity in finished drug product.
Labeling: Product Contains Undeclared API; Incorrect formulation
Subpotent Drug: FDA analysis found these products to be less than the labeled claim for the levothyroxine (T4) portion of the product.
Subpotent Drug: FDA analysis found these products to be less than the labeled claim for the levothyroxine (T4) portion of the product.
CGMP deviations; repackaged product was recalled by the manufacturer because it was manufactured under the same conditions as products found to be sub-potent.
Subpotent Drug